Venous thromboembolism and lung cancer: a review

Venous thromboembolism and lung cancer: a review

Venous thromboembolism (VTE) is a common complication of malignancies and epidemiological studies suggest that lung cancer belonged to the group of malignancies with the highest incidence rates of VTE. Risk factors for VTE in lung cancer patients are adenocarcinoma, NSCLC in comparison with SCLC, ad...

Full description

Bibliographic Details
Main Authors: Vitale, Carolina, D’Amato, Maria, Calabrò, Paolo, Stanziola, Anna Agnese, Mormile, Mauro, Molino, Antonio
Format: Online
Language:English
Published: BioMed Central 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570636/
id pubmed-4570636
recordtype oai_dc
spelling pubmed-45706362015-09-16 Venous thromboembolism and lung cancer: a review Vitale, Carolina D’Amato, Maria Calabrò, Paolo Stanziola, Anna Agnese Mormile, Mauro Molino, Antonio Review Venous thromboembolism (VTE) is a common complication of malignancies and epidemiological studies suggest that lung cancer belonged to the group of malignancies with the highest incidence rates of VTE. Risk factors for VTE in lung cancer patients are adenocarcinoma, NSCLC in comparison with SCLC, advanced disease, pneumonectomy, chemotherapy including antiangiogenic therapy. Other risk factors are pretreatment platelet counts and increased release of TF-positive microparticles. Elevated D-dimer levels do not necessarily indicate an increased risk of VTE but have been shown to be predictive for a worse clinical outcome in lung cancer patients. Mechanisms responsible for the increase in venous thrombosis in patients with lung cancer are not understood. BioMed Central 2015-09-15 /pmc/articles/PMC4570636/ /pubmed/26380084 http://dx.doi.org/10.1186/s40248-015-0021-4 Text en © Vitale et al. 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Vitale, Carolina
D’Amato, Maria
Calabrò, Paolo
Stanziola, Anna Agnese
Mormile, Mauro
Molino, Antonio
spellingShingle Vitale, Carolina
D’Amato, Maria
Calabrò, Paolo
Stanziola, Anna Agnese
Mormile, Mauro
Molino, Antonio
Venous thromboembolism and lung cancer: a review
author_facet Vitale, Carolina
D’Amato, Maria
Calabrò, Paolo
Stanziola, Anna Agnese
Mormile, Mauro
Molino, Antonio
author_sort Vitale, Carolina
title Venous thromboembolism and lung cancer: a review
title_short Venous thromboembolism and lung cancer: a review
title_full Venous thromboembolism and lung cancer: a review
title_fullStr Venous thromboembolism and lung cancer: a review
title_full_unstemmed Venous thromboembolism and lung cancer: a review
title_sort venous thromboembolism and lung cancer: a review
description Venous thromboembolism (VTE) is a common complication of malignancies and epidemiological studies suggest that lung cancer belonged to the group of malignancies with the highest incidence rates of VTE. Risk factors for VTE in lung cancer patients are adenocarcinoma, NSCLC in comparison with SCLC, advanced disease, pneumonectomy, chemotherapy including antiangiogenic therapy. Other risk factors are pretreatment platelet counts and increased release of TF-positive microparticles. Elevated D-dimer levels do not necessarily indicate an increased risk of VTE but have been shown to be predictive for a worse clinical outcome in lung cancer patients. Mechanisms responsible for the increase in venous thrombosis in patients with lung cancer are not understood.
publisher BioMed Central
publishDate 2015
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570636/
_version_ 1613476077112393728

Similar Items